Our team has a unique background of biopharma consulting and finance. After years of working with biopharma companies, we leverage our industry expertise and strategy background to provide informed insights into biotech investing. We founded WX Capital with the hope of providing affordable and digestible biotech research to the public, demystifying biotech and opening up new opportunities for those interested in learning more about this fast-growing and cutting-edge space.
We apply our own research when making investment decisions for our stock portfolio. Through these insights, we have consistently returned >35% annually using the same thorough approach we provided for our biopharma clients.
Kurt has extensive prior experience in life sciences strategy consulting, medical device design, and wet lab research, with a particular focus on global access to care.
Prior to joining WX Capital, Kurt worked at ClearView Healthcare Partners, the leading boutique consulting firm for biopharma companies. While at ClearView, Kurt executed a range of projects including but not limited to corporate strategy, buy/sell-side due diligence, opportunity assessment, and global pricing and
market access strategy, across a breadth of therapeutic areas including rare disease, oncology, large chronic disease, over-the-counter products, and diagnostics.
Kurt earned his B.S. in Biomedical Engineering from Brown University, graduating with Honors and Magna Cum Laude. While at Brown University, Kurt engaged in extensive wet lab research focused on microfluidic point-of-care diagnostics, co-authored a literature review on the field of point-of-care molecular diagnostics, and launched and field-tested a low-cost prosthetic device design project.
Brandon's entire professional career has been dedicated to life sciences, including work in consulting, global pharmaceutical pricing, and biologics R&D.
Prior to joining WX Capital, Brandon worked at ClearView Healthcare Partners, the leading boutique consulting firm for biopharma companies. Brandon was a thought leader on projects related to pricing and market access, buy/sell-side due diligence, opportunity assessments, corporate/business development, and patient claims analytics covering a wide range of therapeutic areas.
Prior to ClearView, Brandon also worked for Pfizer Inc., Merck & Co., and Morgan Stanley covering a broad range of commercial and research roles in the pharmaceutical and biotech industry.
Brandon earned his B.S. in Chemical and Biomolecular Engineering from the Johns Hopkins University, graduating with Honors and as a member of Tau Beta Pi honor society. While at Hopkins, Brandon engaged in research focused on therapeutic targets for stroke, viral particle detecting materials, and pharmacokinetic and dynamic modeling.